Calton & Associates, Inc. Biomarin Pharmaceutical Inc Transaction History

Calton & Associates, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 12, 2022	SELL	$74.28 - $92.69 $185,700 - $231,725	-2,500 Closed	0 $0
Q4 2021 Jan 13, 2022	BUY	$71.72 - $91.47 $179,300 - $228,675	2,500 New	2,500 $220,000
Q3 2021 Nov 05, 2021	SELL	$74.77 - $85.47 $188,869 - $215,897	-2,526 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$75.51 - $84.79 $190,738 - $214,179	2,526 New	2,526 $211,000
Q1 2021 May 03, 2021	SELL	$74.73 - $90.69 $194,821 - $236,428	-2,607 Closed	0 $0
Q4 2020 Jan 25, 2021	BUY	$72.61 - $90.2 $189,294 - $235,151	2,607 New	2,607 $229,000
Q3 2020 Oct 30, 2020	SELL	$71.87 - $131.03 $121,675 - $221,833	-1,693 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$79.55 - $124.22 $134,678 - $210,304	1,693 New	1,693 $209,000
Q1 2018 Apr 17, 2018	SELL	$77.67 - $92.63 $3,339 - $3,983	-43 Closed	0 $0
Q4 2017 Feb 05, 2018	BUY	$80.76 - $95.13 $3,472 - $4,090	43	43 $3,000

633

184M

1.67M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.7B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Calton & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Calton & Associates, Inc. with notifications on news.